Ownership Submission
FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
Ekman Lars
  2. Issuer Name and Ticker or Trading Symbol
AMARIN CORP PLC\UK [AMRN]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
(Last)
(First)
(Middle)
C/O AMARIN PHARMA, INC., 1430 ROUTE 206
3. Date of Earliest Transaction (Month/Day/Year)
03/11/2014
(Street)

BEDMINSTER, NJ 07921
4. If Amendment, Date Original Filed(Month/Day/Year)
6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)
7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)
6. Date Exercisable and Expiration Date
(Month/Day/Year)
7. Title and Amount of Underlying Securities
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)
11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy) $ 1.87 03/11/2014   A   28,500     (1) 03/11/2024 Ordinary Shares (2) 28,500 $ 0 28,500 D  
Stock Option (right to buy) $ 1.87 03/11/2014   A   6,390     (3) 03/11/2024 Ordinary Shares (2) 6,390 $ 0 6,390 D  
Restricted Stock Units (4) 03/11/2014   A   24,000     (4)   (4) Ordinary Shares (2) 24,000 $ 0 24,000 D  
Restricted Stock Units (5) 03/11/2014   A   5,348     (5)   (5) Ordinary Shares (2) 5,348 $ 0 5,348 D  

Reporting Owners

Reporting Owner Name / Address Relationships
 Director  10% Owner  Officer  Other
Ekman Lars
C/O AMARIN PHARMA, INC., 1430 ROUTE 206
BEDMINSTER, NJ 07921
  X      

Signatures

 /s/ Michael Farrell, by power of attorney   03/13/2014
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) This option vests in full upon the earlier of (i) the one-year anniversary of the grant date of March 11, 2014 or (ii) the Issuer's annual meeting of stockholders to be held in 2015.
(2) The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
(3) This option vests in full on January 1, 2015.
(4) On March 11, 2014, the Reporting Person was granted 24,000 restricted stock units (the "RSUs") under the Amarin Corporation plc 2011 Stock Incentive Plan. Each RSU represents a contingent right to receive one Ordinary Share or cash in lieu thereof at the Issuer's discretion, with settlement to be made on a deferred basis, specifically upon the non-employee director's separation of service with the Company. The RSUs vest in equal annual installments over a three-year period, with each installment vesting each year upon the earlier of (i) the anniversary of the grant date of March 11, 2014 or (ii) the Issuer's annual meeting of stockholders in such year.
(5) On March 11, 2014, the Reporting Person was granted 5,348 restricted stock units (the "Additional RSUs") under the Amarin Corporation plc 2011 Stock Incentive Plan. Each Additional RSU represents a contingent right to receive one Ordinary Share or cash in lieu thereof at the Issuer's discretion, with settlement to be made on a deferred basis, specifically upon the non-employee director's separation of service with the Company. The Additional RSUs vest in equal annual installments on January 1, 2015, January 1, 2016 and January 1, 2017, such that the Additional RSUs are fully vested on January 1, 2017.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.